
Sponsors

University of Minnesota

College of Veterinary Medicine

College of Food, Agricultural and Natural Resource Sciences

Extension Service

Swine Center

Thank you to **IDEXX Laboratories** for their financial support to reproduce the conference proceeding book.

Production Leader

Steven Claas

Production Assistant

Steven Claas

Janice Storebo

Sarah Summerbell

Layout and CD-ROM

David Brown

Tina Smith

Logo Design

Ruth Cronje, and Jan Swanson;

based on the original design by Dr. Robert Dunlop

The University of Minnesota is committed to the policy that all persons shall have equal access to its programs, facilities, and employment without regard to race, color, creed, religion, national origin, sex, age, marital status, disability, public assistance status, or sexual orientation.

Results obtained with a novel PCV2 vaccine to protect multiple ages of pigs against PCVAD

R. Desrosiers¹, E. Clark², D. Tremblay³, R. Tremblay¹, and D. Polson⁴

¹Boehringer Ingelheim Canada, Burlington, Ontario, ²CARE Centre, Calgary, Alberta, ³Vetcopor Consultants, St-Lambert-de-Lauzon, Quebec, ⁴Boehringer Ingelheim Vetmedica, Inc., Ames, Iowa

Introduction

This paper describes results obtained with a new PCV2 vaccine, Ingelvac® CircoFLEX™ (Boehringer Ingelheim Vetmedica, Inc.), in Canadian pigs vaccinated at different ages.

Material and Methods

The herd chosen for this blinded study consisted of a multiple site 1300-sow system that had consistently suffered PCVAD losses for about 18 months. These losses occurred exclusively in finishing units, and usually started about 3-4 weeks post placement. The pigs received either 1 mL of placebo (sterile water for injection, group A) or 1 mL of the Ingelvac CircoFLEX vaccine (group B). The injections were all administered in the nursery on the same day, when pigs were between 19 and 59 days of age. The first finishing barn was filled with pigs that had been injected between 45 and 59 days of age (Barn 1). The other three barns were filled with pigs that had been injected at 38 to 45 (Barn 2), 22 to 36 (Barn 3) and 19 to 22 (Barn 4) days of age respectively. In all four barns, pens of group A pigs alternated with pens of group B pigs so that potential exposure would be similar.

Results

Approximately 3850 pigs were part of the study, of which approximately 50% received placebo and 50% the test vaccine. No local or systemic reactions of any kind were noted immediately following injection, or in the days and weeks that followed. As was the case historically in this system, pigs began to show clinical signs of PCVAD about three to four weeks post placement in finishing (80 to 90 days of age), in all four finishing units of the study. Gross and histologic lesions as well as immunohistochemistry results were all compatible with a diagnosis of PCVAD. Vaccinated pigs, regardless of age of vaccination, had a significant reduction in mortality compared to unvaccinated pigs in all 4 finishing barns (Table 1).

Conclusions

Excellent efficacy was achieved whether pigs were vaccinated as young as 19-22 days, or as old as 45-59 days of age. These results suggest that pigs could be effectively vaccinated at an early age. The data also suggest that immunity was relatively quick to develop, since pigs vaccinated only about four weeks before clinical signs were initially observed were protected.

Table 1: Finishing mortality rates

	Treatment	Number of pigs placed	Age (days) at vaccination	Mortality ^a (%)	P value ^b
Barn 1	Sterile water	647	45-59	9.6	< 0.001
	Vaccine	633	45-59	3.0	
Barn 2	Sterile water	260	38-45	8.1	= 0.002
	Vaccine	286	38-45	2.1	
Barn 3	Sterile water	745	22-36	10.6	< 0.001
	Vaccine	717	22-36	2.8	
Barn 4	Sterile water	275	19-22	7.6	< 0.001
	Vaccine	274	19-22	0.4	
Wtd Avg	Sterile water	1,927	19-59	9.5	< 0.001
	Vaccine	1,910	19-59	2.4	

^aMortality includes animals that died or were euthanized for necropsy because of poor condition.

^bWithin farm (individual barn-level) statistical analysis utilized the two-sample proportions test, where H₀: Vaccinates = Controls.

^cStatistical analysis utilized the one-way analysis of variance test, where H₀: Vaccinates = Controls.